CD8+ T cells Are Preferentially Activated during Primary Low Dose Leishmania major Infection but Are Completely Dispensable during Secondary Anti-Leishmania Immunity

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Okwor, Ifeoma B ^a   Jia, Ping ^a   Mou, Zhirong ^a   Onyilagha, Chukwunonso ^a   Uzonna, Jude E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE RESISTANCE; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; INFECTION SENSITIVITY; LEISHMANIA; LEISHMANIASIS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PARASITE IMMUNITY; T CELL DEPLETION;

EID: 84920366926     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003300     Document Type: Article

References (23)

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
2. Varkila K, Chatelain R, Leal LM, Coffman RL, (1993) Reconstitution of C.B-17 scid mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection. European journal of immunology 23: 262–268.
3. Uzonna JE, Joyce KL, Scott P, (2004) Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells. J Exp Med 199: 1559–1566.
4. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992–4000.
5. Titus RG, Marchand M, Boon T, Louis JA, (1985) A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite immunology 7: 545–555.
6. Zaph C, Uzonna J, Beverley SM, Scott P, (2004) Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nature medicine 10: 1104–1110.
7. Liu D, Zhang T, Marshall AJ, Okkenhaug K, Vanhaesebroeck B, et al. (2009) The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. Journal of immunology 183: 1921–1933.
8. Redeker A, Welten SP, Arens R, (2014) Viral inoculum dose impacts memory T-cell inflation. Eur J Immunol 44: 1046–57.
9. Henrickson SE, Perro M, Loughhead SM, Senman B, Stutte S, et al. (2013) Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39: 496–507.
10. Okwor I, Mou Z, Liu D, Uzonna J, (2012) Protective immunity and vaccination against cutaneous leishmaniasis. Frontiers in immunology 3: 128.
11. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, et al. (2002) CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. Journal of immunology 168: 3992–4000.
12. Muller I, Kropf P, Louis JA, Milon G, (1994) Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major. Infect Immun 62: 2575–2581.
13. Muller I, Kropf P, Etges RJ, Louis JA, (1993) Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 61: 3730–3738.
14. Iezzi G, Karjalainen K, Lanzavecchia A, (1998) The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 8: 89–95.
15. van Stipdonk MJ, Lemmens EE, Schoenberger SP, (2001) Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nature immunology 2: 423–429.
16. del Rio ML, Bernhardt G, Rodriguez-Barbosa JI, Forster R, (2010) Development and functional specialization of CD103+ dendritic cells. Immunol Rev 234: 268–281.
17. den Haan JM, Bevan MJ, (2002) Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 196: 817–827.
18. Kaech SM, Wherry EJ, Ahmed R, (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nature reviews Immunology 2: 251–262.
19. Greenblatt CL, (1988) Cutaneous leishmaniasis: The prospects for a killed vaccine. Parasitol Today 4: 53–54.
20. Greenblatt CL, (1980) The present and future of vaccination for cutaneous leishmaniasis. Progress in clinical and biological research 47: 259–285.
21. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, et al. (2005) Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23: 3642–3648.
22. Uzonna JE, Spath GF, Beverley SM, Scott P, (2004) Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. Journal of immunology 172: 3793–3797.
23. Menon JN, Bretscher PA, (1996) Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur J Immunol 26: 243–249.